Besides the examination of the PKC/TCL1/AKT route in CLL, these results led to the in vitro evaluation of enzastaurin, which inhibits both PKCβ and AKT, for therapeutic activity in CLL cells and subsequently to clinical trials (NCT00452257; Figure 1). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.